Visionisti Oy is a privately held company, which is specialized in developing and commercializing a new suprachoroidal injection tool for ophthalmic drug delivery.

1. A New Ocular
Therapeutics Tool
Looking for business opportunities
Timo Kangastupa
Managing Director, Visionisti Oy
non-confidential

2. 30-50M patients with AMD
out of whom 3-10M have the wet form - an overwhelming burden
67M with glaucoma
uveitis, corneal infections, gene therapy, stem cell treatments, and others
350M with diabetic retinopathy
potential therapies for oedemas, RVO, and others

3. 6M IVT injections estimated
in USA during 2016
More than twice the number of
cataract procedures!!! [1], [2], [3]

4. Double-digit continued growth
he number of IVT injections mayreach nearly6 million in 2016." ...more than twice the number of cataract procedures!!!
projected, driven by aging population and new indications

5. “
“Dose reduction and convenience
technologies are needed”
Kevin Buehler
Former Alcon Division Head
Novartis Investor Day
22 November 2013

6. A new solution for
suprachoroidal
injections
Suitable also for precisely transmitting heat,
cold, electricity, light or other energy to directly
stimulate, damage, or heal a specific tissue or
for diagnostic purposes

7. “
“An effective drug delivery system for the
back of the eye should embody four
general characteristics. Current methods
cannot meet all of these requirements.”
- SR Patel, Co-founder Clearside Biomedical

8. 1.
Minimally invasive and safe
to avoid the complications caused by the procedure

9. Fulfilled by Visionist’s Tool:
• Does not penetrate the delicate tissues
• No need for a surgical operation – in office procedure
• Closes the entry wound automatically
• Minimizes the risk for endophthalmitis
• Less discomfort for the patients and faster wound
healing

10. 2.
Well targeted to the
desired tissues
high bioavailability while reducing
adverse events and toxicity

11. Fulfilled by Visionist’s Tool:
• Direct contact to the sites of therapeutic action
• Effective distribution and faster influence
• Limits exposure to other regions of the eye
• Less side effects and complications
• Does not effect the optical axis

12. 3.
Capable of sustained delivery
to reduce the frequency of administration and
allow for better therapeutic control

13. Fulfilled by Visionist’s Tool:
• Higher drug concentrations for months
• More accurate dosing and dose sparing
• Suitable for sustained delivery and implants
• Eases the treatment burden for all parties

14. 4.
Simple
to reduce errors and compliance problems

15. Fulfilled by Visionist’s Tool:
• Repeatable, Faster, Easier and Safer
• Standardizes the procedure and increases the
efficiency
• Stabilizes the eye and keeps the lids open
• Enables administration by trained non-physicians?
• Disposable product with great margins
• Class I medical device

16. Proof of concept – ex vivo porcine eyes
• The distribution of methylene blue in
the suprachoroidal space (black
arrows).
• 1 μm FluoSpheres (below in red) were
localized in the suprachoroidal space.
CONCLUSIONS: The proprietary ocular injection
device is well suitable for precise delivery of
injected material into suprachoroidal space.
Data on file

17. IPR
Multiple
international
patents
pending
FTO
Thoroughly
analysed
No obstacles*
Registered
Community
Designs in EU,
Pending in USA

18. Business opportunities
Rare technology, rare opportunity.
Superior to the known alternatives for
suprachoroidal drug delivery.
Visionisti Oy is open for any kind of business
opportunities you are interested in.
Visionisti presents a novel delivery platform
for your molecules, with no limitations.

19. Thank you!
Please get in touch with
any questions
You can reach me at timo@vsn.st